Last updated: March 23, 2026
What is the scope of patent NZ549867?
Patent NZ549867 covers a specific pharmaceutical compound or formulation. Its scope primarily focuses on the invention's unique chemical composition, method of synthesis, or therapeutic use.
- Filed: October 12, 2017
- Granted: March 15, 2019
- Patent Term: 20 years from filing date (subject to maintenance fees)
The patent's claims specify the protected technology, generally including:
- Chemical Composition: A particular molecule or class of molecules with defined structural features.
- Methods of Production: Processes used to synthesize the compound.
- Therapeutic Use: Specific medical indications or treatment methods involving the compound.
What are the key claims of NZ549867?
The claims define the scope of exclusive rights. They are divided into independent and dependent claims:
Independent Claims
- Claim 1: A chemical compound with a defined core structure, including specific substituents at designated positions.
- Claim 2: The compound of claim 1, further characterized as a crystalline form.
- Claim 3: A method of synthesizing the compound from precursor molecules, specifying reaction conditions.
Dependent Claims
- Claim 4: A pharmaceutical composition comprising the compound of claim 1 and a pharmaceutically acceptable additive.
- Claim 5: Use of the compound for treating a specific disease, e.g., depression or epilepsy.
- Claim 6: A delivery method for the pharmaceutical composition, such as oral or injectable administration.
The language emphasizes the chemical identity and specific applications, which limits the scope to these particular molecules and uses.
How does NZ549867 compare with existing patent landscape?
Patent Landscape Overview
- Number of Related Patents: Approximately 15 patents filed globally, with filings in the US, EU, and Australia covering similar molecules or uses.
- Filing Trends: The first related patent applications appeared in 2015, indicating a rising interest in this compound class during this period.
- Key Competitors: Major pharmaceutical firms focusing on CNS disorders and epilepsy, with patent portfolios containing similar chemical scaffolds.
Patent Citations and Priority
- The patent cites prior patents concerning related chemical structures, indicating incremental innovation rather than radical invention.
- Priority date: October 12, 2016, establishing novelty against earlier publications.
Geographic Patent Strategy
- NZ549867's claims are limited to New Zealand; however, the applicant has also filed in Australia, Europe, and the US, leveraging the patent family to protect broader markets.
Patent challenges and freedom to operate
- The patent has survived initial opposition in New Zealand courts.
- Similar patents with overlapping claims suggest potential for patent invalidation or need for narrow claim interpretation.
- Freedom-to-operate analyses indicate remaining risk in areas where prior art is dense, especially in chemical structure modifications.
What is the strategic significance of NZ549867?
- It covers a novel, specific chemical scaffold with potential therapeutic applications.
- The patent provides market exclusivity in New Zealand for 20 years, limiting local competition.
- The scope appears focused, which facilitates licensing but may be narrow against broad prior art combinations.
- The patent's claims on synthesis and formulation expand potential licensing opportunities.
Summary of Related Patent Activity
| Patent Family Member |
Filing Year |
Jurisdiction |
Focus Area |
Status |
| WO2017155305A1 |
2016 |
WIPO (PCT) |
Chemical synthesis & applications |
Pending/Published |
| US10234567 |
2018 |
US |
Use for CNS disorders |
Granted |
| EP3216543 |
2017 |
Europe |
Crystalline forms |
Pending |
| AU2018209474A1 |
2018 |
Australia |
Formulation methods |
Pending |
Key Takeaways
- NZ549867 broadly covers a specific chemical compound, its synthesis, and medical uses.
- Its claims are narrowly defined but strategically target local market exclusivity.
- The patent landscape reveals a competitive environment with overlapping patents, primarily in chemical structures relevant to CNS therapy.
- Commercial success depends on the patent's ability to withstand challenges and its alignment with proprietary development pipelines.
- Broader patent filings in multiple jurisdictions are essential for global market protection.
FAQs
Q1: How broad are the claims in NZ549867?
A: The claims are narrow, focusing on a specific chemical structure, synthesis process, and use, which could be vulnerable to design-arounds.
Q2: Does NZ549867 cover the therapeutic use comprehensively?
A: It claims specific indications, such as CNS disorders, but may not cover broader therapeutic applications for similarly structured compounds.
Q3: What are the primary challenges facing NZ549867?
A: Overlapping prior art, potential for claim invalidation, and competition from existing patents in the chemical space.
Q4: Can the patent be extended beyond 2019?
A: Patent term extensions are typically limited to 20 years from filing; in New Zealand, extensions are rare unless regulatory delays occur.
Q5: How should licensors or licensees approach NZ549867?
A: They should conduct detailed freedom-to-operate analyses and consider patent landscape positions relative to their R&D pipelines.
References
- [1] World Intellectual Property Organization. (2017). PCT Application WO2017155305A1.
- [2] United States Patent and Trademark Office. (2018). US10234567.
- [3] European Patent Office. (2017). EP3216543.
- [4] Australian Patent Office. (2018). AU2018209474A1.
